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HYDROXYLASE DEFICIENCY 
 
Introduction 
Congenital adrenal hyperplasia (CAH) comprises of a group of 
inherited autosomal disorders affecting the steroid synthesis. The most 
common type is 21 hydroxylase deficiency. Treatment of CAH mainly aims 
at maintaining the normal growth velocity and attaining normal puberty. 
Accumulation of steroid precursors, occasional occurrence of precocious 
puberty can alter the normal growth and pubertal patterns. The control of the 
disease is often difficult and they may need supraphysiological doses of 
steroids which may lead to complications. 
Aims & Objectives 
The aim of this study is to determine the prevalence of short stature and 
other growth disorders, the prevalence of obesity, hypertension and metabolic 
complications in adolescents with CAH, 21 hydroxylase deficiency and also 
to assess the effect of glucocorticoid dosing on growth, obesity, blood 
pressure and metabolic profile. 
Materials and Methods 
This study was conducted in the outpatient department of Child health 
I, Christian Medical College (CMC), Vellore. All adolescent children 
between 10 – 22 years of age diagnosed with CAH 21 hydroxylase deficiency 
in CMC and on regular follow up till adolescence attending the outpatient 
department from February 2016- September 2016 were included in the study. 
Data regarding demography, treatment details, height and body mass index 
were collected. All patients underwent biochemical testing for metabolic 
profile like lipid profile, alanine aminotransferase, fasting glucose and fasting 
insulin. 17 hydroxy progesterone (17 OHP) levels done at regular intervals 
were collected from previous records, for analyzing the adequacy of the 
treatment. The dosage of hydrocortisone per body surface area was collected 
from the patient’s chart since the time of diagnosis. 
 
 Results 
Twenty six patients were included in the study of which 16 were 
females (62%) and 10 were males (38%). Salt wasting was the most common 
type seen among the patients with 65% (n=17) of the total study population. 
Around 23% (n=6) of patients had Short stature as defined by height SDs <-
2. Obesity and overweight was found in 39% (n=10) and 15% (n=4) 
respectively. Abnormal lipid profiles were seen in majority of the children 
with CAH (Hypercholesterolemia in 46%, Abnormal HDL in 35%, abnormal 
LDL in 31%) and insulin resistance was seen in two patients. Short stature 
and obesity was more prevalent in children with CAH compared to the 
general population.  
The risk of short stature was more when the disease control is not 
adequate in adolescent age group. During the adolescent period, 28% (n=5) 
had short stature in the uncontrolled disease activity group compared to 20% 
(n=1) in the group with suppressed 17 OHP level. The risk of obesity is more 
when the disease control is not adequate both during childhood and 
adolescence. 61% of patients with elevated 17 OHP levels during childhood 
and 62% of patients with elevated 17 OHP levels during adolescence had 
overweight and obesity indicating that obesity are more due to poor disease 
control.  
Metabolic abnormalities like dyslipidemia were more prevalent when 
the 17 OHP values were unsuppressed during both the age periods but more 
during the adolescent period. Higher Steroid dosing as defined by dose 
>15mg/m2/day demonstrated no significant effect on short stature and body 
mass index. Transient hypertension was seen in two patients receiving 
fludrocortisone. Insulin resistance was seen in two patients in our study 
population and both the patients had received higher dose of glucocorticoids. 
Conclusion 
 We conclude that adequate suppression of adrenal androgens as 
measured by 17 OHP levels is important during both the childhood and 
adolescent periods to attain normal adult height and normal BMI. 
Unsuppressed 17 OHP values during both the childhood and adolescent age 
group was also a major risk for obesity and overweight. Metabolic 
abnormalities like dyslipidemia were more deranged when the 17 OHP 
values were unsuppressed, more during the adolescent period. Higher Steroid 
dosing demonstrated no significant effect on stature, body mass index and 
metabolic abnormalities. We conclude that dose of 10-15mg/m2/day of 
hydrocortisone seemed to be safer. 
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